Vertex Pharmaceuticals
Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
VRTX Key Statistics
Stock Snapshot
With a market cap of 121.89B, Vertex Pharmaceuticals(VRTX) trades at $480.25. The stock has a price-to-earnings ratio of 28.77.
On 2026-07-13, Vertex Pharmaceuticals(VRTX) stock traded between a low of $474.71 and a high of $485.43. Shares are currently priced at $480.25, which is +1.2% above the low and -1.1% below the high.
Vertex Pharmaceuticals(VRTX) shares are trading with a volume of 1.15M, against a daily average of 2.54M.
In the last year, Vertex Pharmaceuticals(VRTX) shares hit a 52-week high of $533.67 and a 52-week low of $362.50.
In the last year, Vertex Pharmaceuticals(VRTX) shares hit a 52-week high of $533.67 and a 52-week low of $362.50.
VRTX News
Key Points Vertex is buying Crinetics Pharmaceuticals for $10 billion. The acquisition could add up to $5 billion in revenue. The move helps to diversify Ver...
UBS raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $585 from $545 and keeps a Buy rating on the shares. TipRanks has entered a new arena in...
Analyst Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Vertex Pharmaceuticals and increased the price target to $600.00 from $598.00....
Analyst ratings
79%
of 33 ratingsMore VRTX News
Vertex Pharmaceuticals (NASDAQ:VRTX) said it has entered into a definitive agreement to acquire Crinetics Pharmaceuticals for $85 per share in cash, a transacti...
Key Points Vertex Pharmaceuticals is making clinical and regulatory progress with some promising candidates. The company's most important business is still pe...
Key Points Vertex is acquiring Crinetics Pharmaceuticals at $85 a share. Crinetics just had its first drug approved by the FDA. Shares now trade slightly bel...
How much a stock's price changes over time is important for most investors, since price performance can both impact your investment portfolio and help you compa...
Vertex Pharmaceuticals (VRTX 0.45%) is a biotech company that has steadily delivered growth to investors, thanks to its dominance in cystic fibrosis (CF) treatm...
Analyst Naz Rahman of Maxim Group reiterated a Buy rating on Vertex Pharmaceuticals, retaining the price target of $575.00. Unlock powerful investing tools and...
On Monday, Crinetics and Vertex entered into a definitive agreement under which Vertex will acquire Crinetics for $85 per share in cash, representing a total eq...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.